JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians (news)

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians
22 February 2023
https://www.biospace.com/article/releases/janone-to-present-important-trial-results-at-annual-meeting-of-american-society-of-interventional-pain-physicians/

JAN 123’s in vitro study on low dose naltrexone vies for the Society’s “Best Research Abstract of the Year”. JanOne, a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present data on two of its investigational pharmaceutical compounds at the American Society of Interventional Pain Physicians (ASIPP) annual meeting in Washington DC in March, 2023, including data from in vitro studies of JAN 123, the low-dose naltrexone that treats complex regional pain syndrome and is being readied for late-stage clinical trials to facilitate FDA approval.